• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    An apparatus includes an intra-body probe and a processor. The intra-body probe includes an electrode, which is configured to contact tissue in a heart. The processor is configured to receive an electrical signal from the electrode, to distinguish a local component, due to the tissue with which the electrode is in contact, in the electrical signal from a remote-field contribution to the signal, and to control a therapeutic procedure applied to the tissue responsively to the distinguished local component. 200-RECEIVE FIRST ECG SIGNAL FROM 200ECG CATHETER ELECTRODE 210 APPLY ABLATION RECEIVE SUBSEQUENT ECG SIGNAL 220 FROM ECG CATHETER ELECTRODE IDENTIFY CHANGES BETWEEN THE 230- SUBSEQUENT AND PREVIOUS ECG SIGNALS IN RESPONSE TO ABLATION DID ECG YES SIGNAL CHANGE? 250f TERMINATE ABLATION PROCEDURE
    公开号:AU2013206487A1
    申请号:U2013206487
    申请日:2013-06-24
    公开日:2014-01-16
    发明作者:Assaf Govari；Athanassios Papaioannou
    申请人:Biosense Webster Israel Ltd；
    IPC主号:A61B5-0452
    专利说明:
    1 REAL TIME ASSESSMENT OF ABLATION FROM ELECTROCARDIOGRAM SIGNALS FIELD OF THE INVENTION [0001] The present invention relates generally to cardiac therapy, and particularly to methods and systems for monitoring cardiac signals during ablation therapy. BACKGROUND OF THE INVENTION [0002] Various techniques are known in the art for cardiac ablation therapy. U.S. Patent Publication No. 2010/0331658, whose disclosure is incorporated herein by reference, describes an open-irrigated catheter system comprising a tip section, a distal insert, and mapping electrodes. The tip section has an exterior wall that defines an open interior region within the tip section. The exterior wall includes mapping electrode openings and irrigation ports. The exterior wall is conductive for delivering radio frequency (RF) energy for an RF ablation procedure. The irrigation ports are in fluid communication with the open interior region to allow fluid to flow from the open interior region through the irrigation ports. The distal insert is positioned within the tip section to separate the open region into a distal fluid reservoir and a proximal fluid reservoir. The mapping electrodes are positioned in the mapping electrode openings in the tip section. [0003] U.S. Patent Publication No. 2007/0006254, whose disclosure is incorporated herein by reference, describes a method of controlling a remote navigation system that orients the distal end of a medical device in response to user inputs, including interrupting the operation of the remote navigation system when the user inputs would navigate the medical device to a location where the impedance exceeds a predetermined value. A method of controlling ablation of cardiac tissue to block an errant signal causing an arrhythmia includes ablating tissue until there is a predetermined reduction in the amplitude of the errant signal or a predetermined reduction in local impedance. [0004] U.S. Patent No. 7,959,630, whose disclosure is incorporated herein by reference, describes assemblies, probes, and methods for creating circumferential lesions in 2 tissue, e.g., the tissue within or around the ostium of a vessel. An ablation probe with an ablative structure can be placed in contact within or around the ostium of the vessel. A diagnostic probe can be introduced through a lumen within the ablation probe and inserted into the vessel. Energy can be provided to the ablative structure to create a circumferential lesion within or around the ostium of the vessel, and the diagnostic structure can be used to diagnose the tissue to determine whether the circumferential lesion can be properly created. [0005] U.S. Patent Publication No. 2006/0253115, whose disclosure is incorporated herein by reference, describes catheters, systems, and methods which are provided for performing medical procedures, such as tissue ablation, adjacent the ostia of anatomical vessels, such as pulmonary veins. A catheter comprises an elongated flexible catheter body including a proximal shaft portion and a distal shaft portion, which has a proximal section pre-shaped to form a curve having an apex sized to be inserted into an anatomical vessel, such as a pulmonary vein, and a distal section configured to contact an ostium of the vessel when the curve apex is inserted within the vessel ostium. The catheter further comprises a steering mechanism configured for decreasing a radius of curvature of the curve. SUMMARY OF THE INVENTION [0006] An embodiment of the present invention provides an apparatus including an intra-body probe and a processor. The intra-body probe includes an electrode, which is configured to contact tissue in a heart. The processor is configured to receive an electrical signal from the electrode, to distinguish a local component, due to the tissue with which the electrode is in contact, in the electrical signal from a remote-field contribution to the signal, and to control a therapeutic procedure applied to the tissue responsively to the distinguished local component. [0007] In some embodiments, the therapeutic procedure includes cardiac ablation therapy. In other embodiments, the intra-body probe includes an additional electrode that is configured to apply an ablation signal to the heart tissue. In other embodiments, the electrode applies an ablation signal to the tissue in the heart. Yet in other embodiments, the signal includes a received electrocardiogram (ECG) signal. In some embodiments, the 3 local component is in response to cardiac electrical activity generated in the heart within a target ablation region, and the remote-field contribution is in response to cardiac electrical activity generated in the heart outside the target ablation region. [0008] In some embodiments, the processor is configured to distinguish the local component by identifying one or more time intervals in the received signal in response to a change therein. In other embodiments, the processor is configured to distinguish the remote-field contribution by detecting no change in the received signal in one or more additional time intervals outside of the one or more identified time intervals. In yet other embodiments, the processor is configured to initiate a termination of an ablation procedure by detecting that the signal within the one or more identified time intervals no longer responds to successive ablation cycles. [0009] There is also provided, in accordance with embodiments of the present invention, a method including receiving an electrical signal from an intra-body probe, which includes an electrode configured to contact tissue in a heart. A local component, due to the tissue with which the electrode is in contact, in the electrical signal is distinguished from a remote-field contribution to the signal. A therapeutic procedure applied to the tissue is controlled responsively to the distinguished local component. [0010] The present invention will be more fully understood from the following detailed description of the embodiments thereof, taken together with the drawings in which: BRIEF DESCRIPTION OF THE DRAWINGS [0011] Fig. 1 is a schematic diagram showing an electrocardiogram ablation monitoring system, in accordance with an embodiment of the present invention; [0012] Fig. 2 is a schematic diagram showing changes in the ECG waveform with successive ablation cycles, in accordance with an embodiment of the present invention; and 4 [0013] Fig. 3 is a flow chart that schematically illustrates a method for monitoring an electrocardiogram signal after successive ablation cycles, in accordance with an embodiment of the present invention. DETAILED DESCRIPTION OF EMBODIMENTS OVERVIEW [0014] Ablation is a known technique for the treatment of various cardiac conditions. In an ablation procedure, an intra-body probe, typically a catheter, is percutaneously inserted into the cardiovascular system of a patient and navigated into the heart to a region of tissue to be ablated. Cardiac ablation can be performed with different modalities, such as cryoablation and radio frequency (RF) ablation therapies wherein the distal tip of the catheter can respectively be used to locally freeze or heat the tissue. In both cases, a lesion with a low conductance is formed. The lesion typically blocks the faulty pathways of the heart's electrical signals causing cardiac dysfunction, such as tachyarrhythmias and atrial fibrillation. [0015] Real time monitoring of electrocardiogram (ECG) signals while performing the ablation therapy is beneficial for assessing the lesion, e.g., to check if the procedure has improved the heart function, or if more ablation needs to be delivered to the patient. Such real time monitoring may prevent terminating the procedure prematurely. However, if too much ablation is applied to the heart tissue, irreparable damage to the heart may result. [0016] Embodiments of the present invention that are described herein provide methods and systems for a real time assessment of electrical signals received by an intra body probe contacting heart tissue during a therapeutic procedure, such as cardiac ablation, so as to control the procedure in response to monitoring the signals. The intra-body probe, typically a catheter comprising an electrode, is navigated into the heart cavity to a target ablation region and receives a cardiac electrical signal from the electrode contacting the target ablation region. [0017] A monitoring system is configured to distinguish, in a received electrical signal a remote-field contribution from a local component of the signal. The signal is 5 typically an electrocardiogram (ECG) signal. The local component is due to the electrical activity at the target ablation region, whereas the remote-field contribution is due to electrical activity outside the target region. The system then controls the therapeutic procedure in response to the distinguished local component by invoking actions, such as by causing the ablation system to automatically terminate the ablation procedure, or by notifying an operator of the system on a monitor of the status of the ablation procedure. Such notification may avoid damage to the heart by over-ablation. SYSTEM DESCRIPTION [0018] Fig. 1 is a schematic diagram showing an electrocardiogram ablation monitoring system 10, in accordance with an embodiment of the present invention. System 10 comprises an ECG system 15, a display monitor 20 for an operator 22 to observe the ECG signal status, and a processor 25 for monitoring the received ECG data. In some embodiments, the system may also comprise ECG body electrodes 30 which may be placed at different positions along a body of a patient 33 and also utilized in monitoring ECG signals. [0019] During a heart ablation procedure, an intra-body probe, typically a catheter 35 comprising an electrode 40 formed at the distal tip, is inserted into patient 33. Catheter 35 is navigated through the patient's cardiovascular system and into a heart 50 to contact a target ablation region 55 in the heart tissue. Electrode 40 of catheter 35 is utilized by ECG system 15 to measure an ECG signal. [0020] In some embodiments, ablation may be applied to region 55 through a separate catheter, or any other appropriate therapeutic procedure, and the ECG signal monitored through catheter 35. In other embodiments utilizing radio frequency (RF) ablation therapy, the electrode at the distal tip of catheter 35 may be used to both receive the ECG signal at region 55 and also apply an RF ablation signal to region 55 from an RF ablation generator 60, as shown in the inset block diagram of Fig. 1. In yet other embodiments, catheter 35 may comprise an RF ablation electrode at the distal tip and a separate electrode formed on the body of catheter 35 typically near the distal tip.
    6 [0021] Positioning electrode 40 to be in contact with ablation region 55 enables the electrode to receive an ECG signal from the region. As is explained in more detail below, the ECG signal comprises a local component due to cardiac electrical activity generated within target ablation region 55, superimposed with remote-field cardiac electrical potentials generated in heart 50 at positions outside target ablation region 55. The blood, for example, can form a conductive path for electrical cardiac activity occurring in any region of the heart outside of target ablation region 55, and relay the activity to catheter electrode 40 contacting the heart tissue in region 55, resulting in a remote-field contribution of the received ECG waveform. [0022] Typically, faulty electrical pathways in region 55 of the heart causing cardiac dysfunction as discussed previously are incrementally removed with successive ablation cycles. As a result, one or more time intervals in which the ECG waveform decreases in amplitude, or changes shape, can be identified as the local component of the electrical cardiac activity detected from region 55, which is responding to the therapeutic cardiac ablation therapy. Processor 25 is configured to identify and track changes in the ECG waveform with the application of successive ablation cycles to the patient. The embodiment of the present invention shown in Fig. 1 is for conceptual clarity and not by way of limitation of the present invention. [0023] Processor 25 typically comprises a general-purpose computer, with suitable front end and interface circuits for receiving ECG waveform data from ECG system 15 from catheter electrode 40 and body electrodes 30 contacting patient 33. The processor may also comprise magnetic, optical, electronic or any appropriate data storage device for storing the received ECG waveform data. The processor may be programmed in software to carry out the functions that are described herein. The software may be downloaded to system 10 in electronic form, over a network, for example, or it may be provided on non transitory tangible media, such as optical, magnetic or electronic memory media. Alternatively, some or all of the functions of processor 25 may be carried out by dedicated or programmable digital hardware components. Based on signals received from the catheter electrode and body electrodes, processor 25 drives display monitor 20 to provide operator 22 with a visual display of the change of the ECG signal in the defined time 7 intervals with successive ablation cycles. Display monitor 20 may also provide status information and guidance regarding the procedure that is in progress. [0024] Fig. 2 is a schematic diagram showing changes in the ECG waveform with successive ablation cycles, in accordance with an embodiment of the present invention. Before the application of ablation therapy, an initial ECG waveform 100 is detected by ECG system 15. After an ablation cycle is applied, a first subsequent ECG waveform 110 changes in response to the ablation relative to initial waveform 100. Processor 25 identifies one or more time intervals of the ECG waveform, such as regions B and D as shown in Fig. 2 where the ECG signal decreases. Processor 25 identifies one or more additional time intervals of the ECG waveform, such as regions A, C, and E where the ECG signal remains unchanged. Regions B and D are assumed to be related to the local component of the received ECG signal and regions A, C, and E are assumed to be related to the remote-field contribution to the ECG signal from electrical cardiac events outside target ablation region 55. [0025] With another ablation cycle as shown in a second subsequent waveform 120, the signal of the ECG waveform in regions B and D continues to decrease as the ablation decreases the local conductivity of the ablated heart tissue. Note that initial ECG waveform 100 prior to ablation is shown as a dotted line 115 on waveforms 110,120 merely for reference and conceptual clarity. Ablation therapy is continued until the system identifies no further changes in the ECG waveform (e.g., in regions B and D) with successive ablation cycles, as shown as a final ECG waveform 130. At this stage, system 10 is configured to terminate the ablation therapy, or to notify operator 22 that the ECG waveform no longer responds to ablation as described previously, so as not to damage the heart tissue. [0026] Fig. 3 is a flow chart that schematically illustrates a method for monitoring an electrocardiogram signal after successive ablation cycles, in accordance with an embodiment of the present invention. In a first receive step 200, a first ECG signal is received from ECG catheter electrode 40. This data is stored, as a first ECG signal data set, in a storage medium within the processor. In an application step 210, ablation is applied to heart 50 in region 55. In a subsequent receive step 220, a subsequent ECG signal is 8 received from ECG catheter electrode 40. In an identification step 230, processor 25 identifies changes between the subsequent and previously acquired ECG signals in response to ablation, typically after the ablation performed in step 210 has ceased. The processor compares the subsequent ECG signal data set to that of previously acquired ECG data sets to identify changes in the ECG signal due to ablation cycles. From the comparison, the processor may identify one or more time intervals in the ECG waveform where the ECG signal has changed due to the ablation. In a decision step 240, processor 25 assesses if, in step 230, there has been a change in ECG signal levels between the subsequent and previous sets of data. If the assessment is positive, i.e., the ECG signals changed, then the flow chart returns to ablation step 210, so that step 210 and step 220 repeat in an iterative process. If in step 240 there has been no change, the ablation procedure is terminated in a termination step 250, typically so as to prevent heart damage due to over-ablation. [0027] The changes occurring in the ECG signal typically occur in particular time intervals as exemplified by time intervals B and D (Fig. 2). Consideration of the waveforms of Fig. 2 and of the flow chart of Fig. 3 demonstrates that waveform 130 corresponds to a remote-field contribution to the ECG signal and that the differences between waveform 130 and waveforms 100, 110, or 120 correspond to a local component of the signal. [0028] Although the embodiment described in Fig. 2 and Fig. 3 refers to the one or more identified time intervals in which the ECG signal responds to ablation, Fig. 2 and Fig. 3 are merely for conceptual clarity and not by way of limitation whatsoever of the embodiments of the present invention. Any change in the ECG waveform shape in the one or more identified time intervals after successive ablation cycles can be related to the local component of the received ECG signal responding to ablation as described previously. [0029] Although the embodiments described herein typically address the real-time monitoring of ECG signals during cardiac ablation therapy, the methods and systems described herein can also be used in other applications, such as in monitoring neuro electrical signals during RF ablation therapy of brain tumors.
    9 [0030] It will thus be appreciated that the embodiments described above are cited by way of example, and that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and sub-combinations of the various features described hereinabove, as well as variations and modifications thereof which would occur to persons skilled in the art upon reading the foregoing description and which are not disclosed in the prior art. Documents incorporated by reference in the present patent application are to be considered an integral part of the application except that to the extent any terms are defined in these incorporated documents in a manner that conflicts with the definitions made explicitly or implicitly in the present specification, only the definitions in the present specification should be considered. [0031] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. [0032] The reference to any prior art in this specification is not and should not be taken as an acknowledgement or any form of suggestion that the prior art forms part of the common general knowledge in Australia.
    权利要求:
    Claims (18)
    [1] 1. An apparatus, comprising: an intra-body probe comprising an electrode, which is configured to contact tissue in a heart; and a processor, which is configured to receive an electrical signal from the electrode, to distinguish a local component, due to the tissue with which the electrode is in contact, in the electrical signal from a remote-field contribution to the signal, and to control a therapeutic procedure applied to the tissue responsively to the distinguished local component.
    [2] 2. The apparatus according to claim 1, wherein the therapeutic procedure comprises cardiac ablation therapy.
    [3] 3. The apparatus according to claim 1, wherein the intra-body probe comprises an additional electrode that is configured to apply an ablation signal to the heart tissue.
    [4] 4. The apparatus according to claim 1, wherein the electrode applies an ablation signal to the tissue in the heart.
    [5] 5. The apparatus according to claim 1, wherein the signal comprises a received electrocardiogram (ECG) signal.
    [6] 6. The apparatus according to claim 1, wherein the local component is in response to cardiac electrical activity generated in the heart within a target ablation region, and the remote-field contribution is in response to cardiac electrical activity generated in the heart outside the target ablation region.
    [7] 7. The apparatus according to claim 1, wherein the processor is configured to distinguish the local component by identifying one or more time intervals in the received signal in response to a change therein. 11
    [8] 8. The apparatus according to claim 7, wherein the processor is configured to distinguish the remote-field contribution by detecting no change in the received signal in one or more additional time intervals outside of the one or more identified time intervals.
    [9] 9. The apparatus according to claim 7, wherein the processor is configured to initiate a termination of an ablation procedure by detecting that the signal within the one or more identified time intervals no longer responds to successive ablation cycles.
    [10] 10. A method, comprising: receiving an electrical signal from an intra-body probe comprising an electrode configured to contact tissue in a heart; distinguishing a local component, due to the tissue with which the electrode is in contact, in the electrical signal from a remote-field contribution to the signal; and controlling a therapeutic procedure applied to the tissue responsively to the distinguished local component.
    [11] 11. The method according to claim 10, wherein controlling the therapeutic procedure comprises controlling a cardiac ablation therapy applied to the tissue.
    [12] 12. The method according to claim 10, wherein controlling the therapeutic procedure applied to the tissue comprises using a catheter to apply an ablation signal to the tissue with an additional electrode.
    [13] 13. The method according to claim 10, wherein controlling the therapeutic procedure applied to the tissue comprises applying an ablation signal to the tissue in the heart with the electrode.
    [14] 14. The method according to claim 10, wherein receiving the electrical signal comprises receiving an electrocardiogram (ECG) signal.
    [15] 15. The method according to claim 10, wherein the local component is in response to cardiac electrical activity within a target ablation region and the remote-field contribution is in response to cardiac electrical activity generated in a region of the heart outside of the target ablation region. 12
    [16] 16. The method according to claim 11, wherein distinguishing the local component comprises identifying one or more time intervals in the received signal in response to a change therein.
    [17] 17. The method according to claim 16, wherein distinguishing the remote-field contribution comprises detecting no change in the received signal in one or more additional time intervals outside of the one or more identified time intervals.
    [18] 18. The method according to claim 17, wherein controlling the therapeutic procedure comprises initiating a termination of a cardiac ablation procedure in response to detecting that the signal within the identified time intervals no longer responds to successive ablation cycles.
    类似技术:
    公开号 | 公开日 | 专利标题
    AU2013206487B2|2017-11-23|Real time assessment of ablation from electrocardiogram signals
    US9757191B2|2017-09-12|Electrophysiology system and methods
    US20150141978A1|2015-05-21|Ablation medical devices and methods for making and using ablation medical devices
    JP2017508528A|2017-03-30|Electrophysiology system
    JP6396175B2|2018-09-26|Using catheter position and temperature measurements to detect movement from the ablation site
    JP2017060758A|2017-03-30|Ablation current measurement
    JP6190890B2|2017-08-30|Reconstruction of cardiac activation signals based on electrical and mechanical methods
    EP3562419B1|2022-02-09|Blood vessel isolation ablation device
    RU2761291C1|2021-12-06|Dynamic ablation and investigation depending on the contact of segmented electrodes
    EP3673846A1|2020-07-01|Device for an electrophysiology procedure
    JP2020182846A|2020-11-12|Using pulmonary vein isolation for patients with atrial fibrillation
    JP2021090749A|2021-06-17|Catheter with multiple sensing electrodes used as ablation electrode
    US20210106249A1|2021-04-15|Lesion assessment using peak-to-peak impedance amplitude measurement
    TOMLINSON et al.2013|Alligator Clips and a Non-sterile Ablation Catheter to Deliver Radiofrequency Energy Through a Brockenbrough Needle: A Simple, Low-cost Method to Facilitate Difficult Transseptal Puncture
    同族专利:
    公开号 | 公开日
    CN103519884A|2014-01-22|
    CN103519884B|2020-06-30|
    JP6309213B2|2018-04-11|
    AU2013206487B2|2017-11-23|
    IL227017A|2017-05-29|
    US20140005664A1|2014-01-02|
    US9554847B2|2017-01-31|
    JP2014008413A|2014-01-20|
    CA2820807C|2019-12-24|
    EP2682064B1|2018-12-26|
    EP2682064A1|2014-01-08|
    CA2820807A1|2014-01-02|
    IL227017D0|2013-12-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4892102A|1984-04-16|1990-01-09|Astrinsky Eliezer A|Cardiac pacing and/or sensing lead and method of use|
    US5579764A|1993-01-08|1996-12-03|Goldreyer; Bruce N.|Method and apparatus for spatially specific electrophysiological sensing in a catheter with an enlarged ablating electrode|
    US5385146A|1993-01-08|1995-01-31|Goldreyer; Bruce N.|Orthogonal sensing for use in clinical electrophysiology|
    US5738105A|1995-10-24|1998-04-14|Angeion Corporation|Method and apparatus for sensing R-waves using both near field and far field sensing simultaneously|
    DE60020514T2|1999-12-28|2006-05-04|Pacesetter, Inc., Sylmar|Method for distinguishing heart-recorded electrical events and corresponding system|
    KR100351817B1|2000-01-13|2002-09-11|엘지전자 주식회사|open-cable receive system and method for diagnosing of open-cable receive system|
    US6408199B1|2000-07-07|2002-06-18|Biosense, Inc.|Bipolar mapping of intracardiac potentials with electrode having blood permeable covering|
    US6405067B1|2000-07-07|2002-06-11|Biosense Webster, Inc.|Catheter with tip electrode having a recessed ring electrode mounted thereon|
    US7419487B2|2000-07-25|2008-09-02|Angiodynamics, Inc.|Apparatus for detecting and treating tumors using localized impedance measurement|
    US6922579B2|2002-12-12|2005-07-26|Scimed Life Systems, Inc.|La placian electrode|
    US7435248B2|2003-09-26|2008-10-14|Boston Scientific Scimed, Inc.|Medical probes for creating and diagnosing circumferential lesions within or around the ostium of a vessel|
    EP1543865B1|2003-12-17|2008-09-17|BIOTRONIK CRM Patent AG|Reduction of inter-chamber interference|
    US7567835B2|2005-04-18|2009-07-28|Medtronic, Inc.|Method and apparatus for identifying oversensing using far-field intracardiac electrograms and marker channels|
    WO2006121883A1|2005-05-05|2006-11-16|Boston Scientific Scimed, Inc.|Steerable catheter for performing medical procedure adjacent pulmonary vein ostia|
    US20070062547A1|2005-07-21|2007-03-22|Carlo Pappone|Systems for and methods of tissue ablation|
    US7907994B2|2007-01-11|2011-03-15|Biosense Webster, Inc.|Automated pace-mapping for identification of cardiac arrhythmic conductive pathways and foci|
    EP3000390A1|2007-03-26|2016-03-30|Boston Scientific Limited|High resolution electrophysiology catheter|
    EP2448510B1|2009-06-30|2016-08-31|Boston Scientific Scimed, Inc.|Map and ablate open irrigated hybrid catheter|
    US8617228B2|2009-10-23|2013-12-31|Medtronic Cryocath Lp|Method and system for preventing nerve injury during a medical procedure|
    US8583215B2|2009-11-05|2013-11-12|Biosense Webster Ltd.|Reduction of catheter electrode loading|
    US8668686B2|2009-12-23|2014-03-11|Biosense Webster Ltd.|Sensing contact of ablation catheter using differential temperature measurements|
    US9539046B2|2010-08-03|2017-01-10|Medtronic Cryocath Lp|Cryogenic medical mapping and treatment device|
    EP2938244A1|2012-12-27|2015-11-04|Boston Scientific Scimed, Inc.|Artifact cancellation to suppress far-field activation during electrophysiology mapping|US9119633B2|2006-06-28|2015-09-01|Kardium Inc.|Apparatus and method for intra-cardiac mapping and ablation|
    US8906011B2|2007-11-16|2014-12-09|Kardium Inc.|Medical device for use in bodily lumens, for example an atrium|
    US9198592B2|2012-05-21|2015-12-01|Kardium Inc.|Systems and methods for activating transducers|
    US10827977B2|2012-05-21|2020-11-10|Kardium Inc.|Systems and methods for activating transducers|
    US9017321B2|2012-05-21|2015-04-28|Kardium, Inc.|Systems and methods for activating transducers|
    EP3603501A1|2012-08-09|2020-02-05|University of Iowa Research Foundation|Catheter systems for surrounding a tissue structure|
    EP3091921B1|2014-01-06|2019-06-19|Farapulse, Inc.|Apparatus for renal denervation ablation|
    WO2015171921A2|2014-05-07|2015-11-12|Mickelson Steven R|Methods and apparatus for selective tissue ablation|
    EP3154463B1|2014-06-12|2019-03-27|Farapulse, Inc.|Apparatus for rapid and selective transurethral tissue ablation|
    EP3154464A4|2014-06-12|2018-01-24|Iowa Approach Inc.|Method and apparatus for rapid and selective tissue ablation with cooling|
    EP3206613B1|2014-10-14|2019-07-03|Farapulse, Inc.|Apparatus for rapid and safe pulmonary vein cardiac ablation|
    US10368936B2|2014-11-17|2019-08-06|Kardium Inc.|Systems and methods for selecting, activating, or selecting and activating transducers|
    US10722184B2|2014-11-17|2020-07-28|Kardium Inc.|Systems and methods for selecting, activating, or selecting and activating transducers|
    US20160174864A1|2014-12-18|2016-06-23|Biosense WebsterLtd.|Far Field-Insensitive Intracardiac Catheter Electrodes|
    US9421061B2|2014-12-18|2016-08-23|Biosense WebsterLtd.|Ventricular far field reduction|
    US9833161B2|2015-02-09|2017-12-05|Biosense WebsterLtd.|Basket catheter with far-field electrode|
    US9706937B2|2015-04-22|2017-07-18|Biosense WebsterLtd.|Ventricular electrical activity indicator|
    CN104783894A|2015-04-22|2015-07-22|杭州睿笛生物科技有限公司|Electrocardiogram monitoring and automatic protection device for electrical ablation of tumors|
    US10660702B2|2016-01-05|2020-05-26|Farapulse, Inc.|Systems, devices, and methods for focal ablation|
    US10172673B2|2016-01-05|2019-01-08|Farapulse, Inc.|Systems devices, and methods for delivery of pulsed electric field ablative energy to endocardial tissue|
    US20170189097A1|2016-01-05|2017-07-06|Iowa Approach Inc.|Systems, apparatuses and methods for delivery of ablative energy to tissue|
    WO2017218734A1|2016-06-16|2017-12-21|Iowa Approach, Inc.|Systems, apparatuses, and methods for guide wire delivery|
    US9987081B1|2017-04-27|2018-06-05|Iowa Approach, Inc.|Systems, devices, and methods for signal generation|
    US10617867B2|2017-04-28|2020-04-14|Farapulse, Inc.|Systems, devices, and methods for delivery of pulsed electric field ablative energy to esophageal tissue|
    US10130423B1|2017-07-06|2018-11-20|Farapulse, Inc.|Systems, devices, and methods for focal ablation|
    EP3681391A1|2017-09-12|2020-07-22|Farapulse, Inc.|Systems, apparatuses, and methods for ventricular focal ablation|
    CN108596132A|2018-04-28|2018-09-28|上海微创电生理医疗科技股份有限公司|Ablation stove evaluation method and system|
    JP2021522898A|2018-05-07|2021-09-02|ファラパルス，インコーポレイテッド|Epicardial ablation catheter|
    JP2021522903A|2018-05-07|2021-09-02|ファラパルス，インコーポレイテッド|Systems, devices, and methods for delivering ablation energy to tissues|
    WO2019217317A1|2018-05-07|2019-11-14|Farapulse, Inc.|Systems, apparatuses, and methods for filtering high voltage noise induced by pulsed electric field ablation|
    CN112955088A|2018-09-20|2021-06-11|法拉普尔赛股份有限公司|Systems, devices, and methods for delivering pulsed electric field ablation energy to endocardial tissue|
    US20200281494A1|2019-03-06|2020-09-10|Biosense WebsterLtd.|Mid-field signal extraction|
    CN110151167A|2019-05-20|2019-08-23|苏州润迈德医疗科技有限公司|A kind of collector and method that can measure electrocardio and invasive blood pressure simultaneously|
    US10625080B1|2019-09-17|2020-04-21|Farapulse, Inc.|Systems, apparatuses, and methods for detecting ectopic electrocardiogram signals during pulsed electric field ablation|
    US11065047B2|2019-11-20|2021-07-20|Farapulse, Inc.|Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses|
    US10842572B1|2019-11-25|2020-11-24|Farapulse, Inc.|Methods, systems, and apparatuses for tracking ablation devices and generating lesion lines|
    EP3960084A1|2020-08-27|2022-03-02|Biosense WebsterLtd|Removing far-field from intracardiac signals|
    法律状态:
    2018-03-22| FGA| Letters patent sealed or granted (standard patent)|
    优先权:
    申请号 | 申请日 | 专利标题
    US13/539,628||2012-07-02||
    US13/539,628|US9554847B2|2012-07-02|2012-07-02|Real time assessment of ablation from electrocardiogram signals|
    [返回顶部]